Paradromics announced in March the upcoming trials for Connexus, an implantable microchip for brain-computer interfacing. The first trial is set for late 2025 pending regulatory approval. This device aims to restore communication in individuals with speech impairment due to conditions like ALS, stroke, or severe spinal cord injuries. Paradromics also envisions broader applications in mental health and chronic pain management.
Looking ahead, successful trials could pave the way for revolutionary advancements in neurotechnology. The potential of implantable microchips for brain-computer interfacing opens doors to improved quality of life for patients with neurological conditions. Furthermore, the expansion of this technology may lead to innovative solutions in various fields, from healthcare to human-computer interaction. Paradromics’ pioneering work highlights the promising future of neural interfaces and their impact on enhancing human capabilities.
Read more from gizmodo.com
